We further explored pharmacological modulation of the clock using the CRY agonist KL001 and the REV-ERB agonist SR9011—agents previously shown to enhance TMZ efficacy, both alone and in combination, in GBM experimental models20,21. The gene discussed is CLOCK; the disease is glioblastoma.